Rxivist logo

Mechanism of SARS-CoV-2 polymerase inhibition by remdesivir

By Goran Kokic, Hauke Sven Hillen, Dimitry Tegunov, Christian Dienemann, Florian Seitz, Jana Schmitzova, Lucas Farnung, Aaron Siewert, Claudia Hoebartner, Patrick Cramer

Posted 28 Oct 2020
bioRxiv DOI: 10.1101/2020.10.28.358481

Remdesivir is the only FDA-approved drug for the treatment of COVID-19 patients. The active form of remdesivir acts as a nucleoside analogue and inhibits the RNA-dependent RNA polymerase (RdRp) of coronaviruses including SARS-CoV-2. Remdesivir is incorporated by the RdRp into the growing RNA product and allows for addition of three more nucleotides before RNA synthesis stalls. Here we use synthetic RNA chemistry, biochemistry and cryo-electron microscopy to establish the molecular mechanism of remdesivir-induced RdRp stalling. We show that addition of the fourth nucleotide following remdesivir incorporation into the RNA product is impaired by a barrier to further RNA translocation. This translocation barrier causes retention of the RNA 3'-nucleotide in the substrate-binding site of the RdRp and interferes with entry of the next nucleoside triphosphate, thereby stalling RdRp. In the structure of the remdesivir-stalled state, the 3'-nucleotide of the RNA product is matched with the template base, and this may prevent proofreading by the viral 3'-exonuclease that recognizes mismatches. These mechanistic insights should facilitate the quest for improved antivirals that target coronavirus replication. ### Competing Interest Statement The authors have declared no competing interest.

Download data

  • Downloaded 1,739 times
  • Download rankings, all-time:
    • Site-wide: 10,494
    • In biochemistry: 208
  • Year to date:
    • Site-wide: 10,362
  • Since beginning of last month:
    • Site-wide: 22,315

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide